Literature DB >> 18202197

Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors.

Toshio Kuwai1, Toru Nakamura, Sun-Jin Kim, Takamitsu Sasaki, Yasuhiko Kitadai, Robert R Langley, Dominic Fan, Stanley R Hamilton, Isaiah J Fidler.   

Abstract

The design of targeted therapy, particularly patient-specific targeted therapy, requires knowledge of the presence and intratumoral distribution of tyrosine kinase receptors. To determine whether the expression of such receptors is constant or varies between and within individual colon cancer neoplasms, we examined the pattern of expression of the ligands, epidermal growth factor, vascular endothelial growth factor, and platelet-derived growth factor-B as well as their respective receptors in human colon cancer surgical specimens and orthotopic human colon cancers growing in the cecal wall of nude mice. The expression of the epidermal growth factor receptor and the vascular endothelial growth factor receptor on tumor cells and stromal cells, including tumor-associated endothelial cells, was heterogeneous in surgical specimens and orthotopic tumors. In some tumors, the receptor was expressed on both tumor cells and stromal cells, and in other tumors the receptor was expressed only on tumor cells or only on stromal cells. In contrast, the platelet-derived growth factor receptor was expressed only on stromal cells in both surgical specimens and orthotopic tumors. Examination of receptor expression in both individual surgical specimens and orthotopic tumors revealed that the platelet-derived growth factor receptor was expressed only on stromal cells and that the patterns of epidermal growth factor receptor and vascular endothelial growth factor receptor 2 expression differed between tumor cells. This heterogeneity in receptor expression among different tumor cells suggests that targeting a single tyrosine kinase may not yield eradication of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18202197      PMCID: PMC2312354          DOI: 10.2353/ajpath.2008.070625

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

1.  Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha.

Authors:  I Atlas; J Mendelsohn; J Baselga; W R Fair; H Masui; R Kumar
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

Review 2.  Signal transduction by receptors with tyrosine kinase activity.

Authors:  A Ullrich; J Schlessinger
Journal:  Cell       Date:  1990-04-20       Impact factor: 41.582

Review 3.  Growth factor receptor tyrosine kinases.

Authors:  Y Yarden; A Ullrich
Journal:  Annu Rev Biochem       Date:  1988       Impact factor: 23.643

4.  In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice.

Authors:  K Morikawa; S M Walker; J M Jessup; I J Fidler
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

5.  Vascular endothelial growth factor is a secreted angiogenic mitogen.

Authors:  D W Leung; G Cachianes; W J Kuang; D V Goeddel; N Ferrara
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

6.  Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

7.  Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.

Authors:  Paul Mathew; Peter F Thall; Donnah Jones; Cherie Perez; Corazon Bucana; Patricia Troncoso; Sun-Jin Kim; Isaiah J Fidler; Christopher Logothetis
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

8.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 9.  PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.

Authors:  Arne Ostman
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

10.  Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Authors:  Fortunato Ciardiello; Roberto Bianco; Roberta Caputo; Rosa Caputo; Vincenzo Damiano; Teresa Troiani; Davide Melisi; Ferdinando De Vita; Sabino De Placido; A Raffaele Bianco; Giampaolo Tortora
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

View more
  17 in total

1.  A digest on the role of the tumor microenvironment in gastrointestinal cancers.

Authors:  Martin Augsten; Christina Hägglöf; Cristina Peña; Arne Ostman
Journal:  Cancer Microenviron       Date:  2010-03-07

2.  HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Natsumi Irahara; Andrew T Chan; Jeffrey A Meyerhardt; Daniel C Chung; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

3.  Cancer immunoediting of the NK group 2D ligand H60a.

Authors:  Timothy O'Sullivan; Gavin P Dunn; Daphne Y Lacoursiere; Robert D Schreiber; Jack D Bui
Journal:  J Immunol       Date:  2011-08-29       Impact factor: 5.422

4.  Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma.

Authors:  Tina Cascone; Matthew H Herynk; Li Xu; Zhiqiang Du; Humam Kadara; Monique B Nilsson; Carol J Oborn; Yun-Yong Park; Baruch Erez; Jörg J Jacoby; Ju-Seog Lee; Heather Y Lin; Fortunato Ciardiello; Roy S Herbst; Robert R Langley; John V Heymach
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

Review 5.  Matrix metalloproteinases: changing roles in tumor progression and metastasis.

Authors:  Laurie A Shuman Moss; Sandra Jensen-Taubman; William G Stetler-Stevenson
Journal:  Am J Pathol       Date:  2012-10-12       Impact factor: 4.307

6.  Angiogenesis and lymphangiogenesis of gastric cancer.

Authors:  Yasuhiko Kitadai
Journal:  J Oncol       Date:  2010-03-29       Impact factor: 4.375

Review 7.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

8.  Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.

Authors:  Toshio Kuwai; Toru Nakamura; Takamitsu Sasaki; Yasuhiko Kitadai; Jang-Seong Kim; Robert R Langley; Dominic Fan; Xuemei Wang; Kim-Anh Do; Sun-Jin Kim; Isaiah J Fidler
Journal:  Clin Exp Metastasis       Date:  2008-03-07       Impact factor: 5.150

Review 9.  Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2012-02-13       Impact factor: 6.208

10.  The relevance of cell type- and tumor zone-specific VEGFR-2 activation in locally advanced colon cancer.

Authors:  Caren Jayasinghe; Nektaria Simiantonaki; Sylvia Habedank; Charles James Kirkpatrick
Journal:  J Exp Clin Cancer Res       Date:  2015-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.